Renaissance Technologies LLC Reduces Stock Position in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD)

Renaissance Technologies LLC lessened its holdings in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Free Report) by 59.8% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 59,491 shares of the company's stock after selling 88,647 shares during the period. Renaissance Technologies LLC owned approximately 0.37% of Cadrenal Therapeutics worth $28,000 at the end of the most recent reporting period.

Cadrenal Therapeutics Price Performance

CVKD remained flat at $14.50 during trading on Tuesday. 53,241 shares of the company traded hands, compared to its average volume of 23,878. Cadrenal Therapeutics, Inc. has a one year low of $5.40 and a one year high of $32.55. The firm has a 50 day moving average of $10.36. The company has a market capitalization of $232.12 million, a price-to-earnings ratio of -46.77 and a beta of 1.81.

Cadrenal Therapeutics (NASDAQ:CVKD - Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($33.75) earnings per share for the quarter, beating analysts' consensus estimates of ($285.60) by $251.85. On average, sell-side analysts forecast that Cadrenal Therapeutics, Inc. will post -6.72 EPS for the current year.

Cadrenal Therapeutics Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.